In this video, James Matera, DO, gives a preview of his presentation on the differences between NASH and NAFLD, which will be presented at the Practical Updates in Primary Care 2020 Virtual Series on...
He talks about the treatment options that are available for treating nonalcoholic fatty liver disease via metabolic pathways. He recently spoke about this topic at the 21st Annual Harvard Nutrition and...
Aveni Haynes, PhD, discusses findings from her new study, which suggested that improvements in HbA1c and decreases in severe hypoglycemia rates have occurred concurrently over the past 2 decades in the...
Dr Speiser answers our questions about the Endocrine Society’s 2018 clinical practice guideline for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency.
Dr Matera reviews recent evidence that has demonstrated the potential renal protection offered by sodium glucose co-transporter 2 inhibitors against diabetic kidney disease.
Endocrinology Consultant spoke with Derek LeRoith, MD, PhD, member of the task force that developed the Endocrine Society’s 2019 clinical practice guideline for the treatment of diabetes in older adults. ...
Endocrinology Consultant spoke with Christian Hampp, PhD, from the US Food and Drug Administration, whose study found high rates of diabetic ketoacidosis when sodium-glucose cotransporter 2 inhibitors are...
Endocrinology Consultant spoke with James Rosenzweig, MD, chair of the task force that developed the Endocrine Society’s clinical practice guideline for the primary prevention of atherosclerotic...
Charles Brenner, PhD, director of the Obesity Initiative at the University of Iowa, discusses properties of nicotinamide riboside that have been uncovered since its initial discovery in 2004.
